INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.

Abstract excerpt

Mutations in the p53 gene are the most frequent genetic alterations in human tumours, occurring in approximately 50% of all cancers. The p53 protein is pivotal in maintaining genetic integrity after DNA damage, and alterations in the p53 pathway, including mutations in the p53 gene, greatly increase the probability of tumour formation. Gene therapy using adenoviral p53 has emerged as a novel treatment option,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenoviridae
• Share to Clinical Trials as Topic
• Share to Combined Modality Therapy